ABSTRACT
Conclusion:
The clinical consequences of COVID-19 disease in young and middle-aged adults were investigated.
Results:
In our current study, delayed recovery rates were observed in those receiving favipiravir treatment (p=0.05). Likewise, delayed recovery rates were observed in those receiving plaquenil treatment such as favipiravir. (p≥0.05).In studies, it was determined that COVID-19 infection affects the coagulation cascade and predisposes to thromboembolic events. It was determined that 40% of patients with a diagnosis of COVID-19 who had clots in their organs received low molecular weight heparin (LMWH) treatment, and 60% did not receive LMWH treatment. Of the study population, 76.65% (348) were non-smokers, and it was found that non-smokers survived the disease milder (p=0.047).
Material and Methods:
Using the SurveyMonkey statistical program, a 31-question questionnaire was filled in 454 devices using digital devices. In addition, SPSS 20 program was used in the statistical evaluation of the data. 55.07% (250) of the participants were between the ages of 18-40, and 42.07% (191) were between the ages of 40-65.
Objective:
The coronavirus disease-2019 (COVID-19) pandemic is a pandemic that has spread all over the world in a short time due to the corona virus, readers of China’s Wuhan, in 2019. It was named severe acute respiratory syndrome coronavirus-2 because the disease especially affects the respiratory tract. There are many studies in the literature for COVID-19, and new ones are still being made. In this case, the effects of COVID-19 on young and middle-aged adults were investigated.
Keywords:
COVID-19, coronavirus, SARS-CoV-2 pandemic
References
1Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chin Med J (Engl) 2020;133(9):1087-1095.
2Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J 2021;23(1):14.
3Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 2020;172(9):577-582.
4Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet 2022;399(10335):1618-1624.
5IDSA. Infectious diseases society of America guidelines on the diagnosis of COVID-19, updated December 23, 2020. (Atıf tarihi: 14 Ocak 2021) Erişim adresi: https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics/.
6Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2. (Atıf tarihi: 21 Eylül 2020). Erişim adresi: https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html
7Mullins E, Evans D, Viner RM, O'Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid review. Ultrasound Obstet Gynecol 2020;55(5):586-592.
8Zhang H, Ma S, Han T, Qu G, Cheng C, Uy JP, et al. Association of smoking history with severe and critical outcomes in COVID-19 patients: A systemic review and meta-analysis. Eur J Integr Med 2021;43:101313.
9Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020;323(18):1775-1776.
10Glanville J, Huang H, Nau A, Hatton O, Wagar LE, Rubelt F, et al. Identifying specificity groups in the T cell receptor repertoire. Nature 2017;547(7661):94-98.
11Kim T. Improving Preparedness for and Response to Coronavirus Disease 19 (COVID-19) in Long-Term Care Hospitals in Korea. Infect Chemother 2020;52(2):133-141.
12Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239-1242.
13Solaymani-Dodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Hassan Saadat S, et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol 2021;95:107522.
14RECOVERY Collaborative Group; Horby P, Mafham M, Linsell L, Bell JL, Staplin N, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020;383(21):2030-2040.
15CDC. Understanding How COVID-19 Vaccines Work. [İnternet] [Atıf tarihi: 1 Eylül 2021]. Erişim linki: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html
16Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med 2022;28(2):410-422.
17Yılmaz Hİ, Turğut B, Çıtlak G, Mert O, Paralı B, Engin M, et al. Türkiye’de İnsanların COVID-19 Aşısına Bakışı. Dicle Tıp Dergisi. 2021;48(3):583-594.
